Biofarm S.A. (BIO) Stock Price, Fundamentals & Analysis

What BIO does

Biofarm S.A. (symbol BIO, ISIN ROBIOFACNOR9) is a stock listed on the Bucharest Stock Exchange (BVB) in the Healthcare sector, specifically in the Drug Manufacturers – Specialty & Generic industry. The company manufactures pharmaceutical products across a wide range of therapeutic areas, including cardiovascular, digestive and metabolic, genito-urinary, ophthalmological, endocrine, nervous system, osteo-muscular, respiratory and ENT, multivitamin, antiallergen, and dermatological products. Founded in 1921 and headquartered in Bucharest, Romania, Biofarm S.A. operates as a subsidiary of Polpharma SA Pharmaceutical Works as of June 24, 2026.

Key numbers explained

• The current price is 1.37 RON, up +0.74% today, with a 52-week range of 0.78 – 1.5 and a 52-week price change of 67.1%.
• The trailing P/E ratio of 19.6 divides the current share price by the last 12 months of earnings per share (0.07 RON); a lower P/E can suggest lower relative valuation, while a higher P/E can reflect higher growth expectations.
• The dividend yield of 3.07% shows the annual dividend as a percentage of the current price; the ex-dividend date is June 29, 2026, and the company pays out 105% of its earnings as dividends.
• Market capitalization of 1.35 mld. RON reflects the total market value of all outstanding shares.
• The beta of 0.51 indicates the stock tends to move about half as much as the overall market, suggesting lower volatility.
• Revenue over the last 12 months was 294.25 mil. RON, down -33.2% year over year, while the profit margin stands at 26.6% and the operating margin at -23.9%.
• Return on equity is 17.6%, and the debt-to-equity ratio of 0.3 shows the company uses relatively little debt compared to equity.
• The price-to-book ratio of 3.42 compares the market price to the book value per share; a ratio above 1 means the market values the company above its accounting net assets.

What to watch

Investors in Biofarm S.A. typically monitor factors common to pharmaceutical and healthcare stocks, such as product pipeline developments, regulatory approvals, generic competition, and changes in drug pricing or reimbursement policies. The company's operating margin is currently negative, so shifts in cost management and revenue trends are worth following. As a subsidiary of Polpharma SA, broader corporate strategy and integration decisions may also affect the stock. For context within the Romanian market, peers such as Ropharma SA (RPH), Farmaceutica Remedia SA (RMAH), and Antibiotice S.A. (ATB) operate in the same sector, while healthcare-focused names like Med Life S.A. (M) and VES SA (VESY) offer additional comparison points.